Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Articles

Cycling of Immune Responses to a Syngeneic Murine Mammary Adenocarcinoma

Sally A. Huber, Giuseppi Bigi and Zoltan J. Lucas
Sally A. Huber
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giuseppi Bigi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zoltan J. Lucas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published October 1980
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Fischer rats immunized i.p. with 103 to 107 syngeneic 13762A mammary adenocarcinoma tumor cells develop a biphasic cytolytic response to the tumor in the spleen. The first (early) cytolytic phase, detected within 4 days of tumor inoculation, peaks on Day 7 and decreases by Day 9. The second (late) cytolytic phase is detected 13 or more days after tumor injection and is maintained until death. Spleen cells obtained 9 to 13 days after inoculation of the 13762A mammary adenocarcinoma lack cytolytic activity and specifically inhibit in vitro generation of cytolytic lymphocytes. The magnitude of either splenic cytotoxicity or suppression is independent of the initial tumor dose. Both early and late cytolytic cells are T-lymphocytes. Cytolysis by early spleen cells is less specific than that by late cytolytic cells, since early lymphocytes lyse a second unrelated F344 mammary adenocarcinoma, R3230. Neither spleen cell population lyses a Moloney sarcoma-induced tumor or a fibrosarcoma from syngeneic rats.

Serological blocking factors are detected in 13762A tumorbearing rats within 4 days following injection of 104 tumor cells. Blocking activity in Day 12 serum appears on Sephacryl S-200 in the immunoglobulin G (IgG) (M.W. 160,000) and low-molecular-weight (M.W. < 70,000) fractions. Blocking activity in Day 20 serum is more polydispersed, separating into the high-molecular-weight (M.W. ≥ 200,000), IgG, and low-molecular-weight fractions. The high-molecular-weight and low-molecular-weight blocking factors probably represent immune complexes and free tumor antigen, respectively; both factors similarly inhibit early and late cytolytic cells. The IgG blocking factor in Day 12 serum, tentatively identified as an anti-receptor antibody, preferentially inhibits the early cytolytic cells; Day 20 IgG preferentially inhibits the late cytolytic cells. Finally, Day 11 suppressor cells preferentially inhibit generation of cytolytic lymphocytes from the early spleen cell population.

These results suggest that the host response to this syngeneic tumor is complex and alternates between phase of cytolytic activity and suppression of the immune response. The cytolytic cells obtained during different phases appear to vary in their ability to be inhibited by both the IgG blocking factors and suppressor cells.

Footnotes

  • ↵1 This study was supported by Contract 1-CB-33905 from NIH; by the Beta Sigma Phi Kidney Transplant Research Fund; by a gift fund donated to Dr. Roy Cohn, Stanford University School of Medicine; and by NIH Grant CA-24725.

  • ↵4 To whom requests for reprints should be addressed.

  • Received February 20, 1980.
  • Accepted July 3, 1980.
  • ©1980 American Association for Cancer Research.
PreviousNext
Back to top
October 1980
Volume 40, Issue 10
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Cycling of Immune Responses to a Syngeneic Murine Mammary Adenocarcinoma
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Cycling of Immune Responses to a Syngeneic Murine Mammary Adenocarcinoma
Sally A. Huber, Giuseppi Bigi and Zoltan J. Lucas
Cancer Res October 1 1980 (40) (10) 3484-3490;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Cycling of Immune Responses to a Syngeneic Murine Mammary Adenocarcinoma
Sally A. Huber, Giuseppi Bigi and Zoltan J. Lucas
Cancer Res October 1 1980 (40) (10) 3484-3490;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Insights from Bcl-2 and Myc: Malignancy Involves Abrogation of Apoptosis as well as Sustained Proliferation
  • Core-Binding Factor: A Central Player in Hematopoiesis and Leukemia
  • Introduction of Stanley J. Korsmeyer
Show more Articles
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement